-+ 0.00%
-+ 0.00%
-+ 0.00%

Xiansheng Pharmaceutical announced that SIM0712, an oral small molecule degrader targeting STAT6 independently developed by the Group, has received a drug clinical trial approval notice issued by the China National Drug Administration to conduct clinical trials for the treatment of atopic dermatitis. SIM0712 was independently developed based on the Group's proteolytic targeting chimera technology platform. Preclinical studies have shown that it has high target activity and selectivity, and has broad application prospects in type 2 inflammatory diseases such as atopic dermatitis and asthma.

Zhitongcaijing·11/16/2026 10:17:22
Listen to the news
Xiansheng Pharmaceutical announced that SIM0712, an oral small molecule degrader targeting STAT6 independently developed by the Group, has received a drug clinical trial approval notice issued by the China National Drug Administration to conduct clinical trials for the treatment of atopic dermatitis. SIM0712 was independently developed based on the Group's proteolytic targeting chimera technology platform. Preclinical studies have shown that it has high target activity and selectivity, and has broad application prospects in type 2 inflammatory diseases such as atopic dermatitis and asthma.